RARA and acute promyelocytic leukemia: Studies indicate that CBG regulates the β‐catenin signaling pathway, modulates the expression of Bax, Bcl‐2, cyclin D1, and c‐myc, and induces caspase‐dependent apoptosis in NB4 and NB4‐r1 cells along with PML‐RARA degradation, offering a novel therapeutic strategy for APL patients [35].